Cerulean Pharma Inc. (CERU)

Oncology Corporate Profile

Stock Performance

1.1200
-0.1000

HQ Location

840 Memorial Drive, 5th Floor
Cambridge, MA 2139

Company Description

Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of tumor-targeted nanopharmaceuticals. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company's technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs.

Website: http://www.ceruleanrx.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CRLX101nanopartical conjugate2nd line metastatic Non Small Cell Lung Cancer (NSCLC)II
CRLX101 nanopartical conjugate2nd line metastatic Renal Cell Carcinoma (RCC)II
CRLX101 (+ bevacizumab) nanopartical conjugate2nd line metastatic Renal Cell Carcinoma (RCC)II
CRLX101nanopartical conjugate2nd line metastatic Small Cell Lung Cancer (SCLC)II
CRLX101nanopartical conjugateGastric cancerII
CRLX101 (+ bevacizumab) nanopartical conjugateOvarian cancerIIGenentech / Roche
CRLX101nanopartical conjugateOvarian cancerII
CRLX101nanopartical conjugateColorectal cancerI
CRLX101 (+ paclitaxel) nanopartical conjugateOvarian cancerI
CRLX101 (+ opalarib) nanopartical conjugateVarious cancer typesIAstraZeneca
CRLX101nanopartical conjugateVarious cancer typesI

View additional information on product candidates here »

Pipeline image

Source


http://www.ceruleanrx.com/

Recent News Headlines

Cerulean and Daré to Host Conference Call on Proposed Transaction on March 23

3/21/2017 01:03 am

[Business Wire] - Cerulean Pharma Inc. , today announced jointly with Daré Bioscience that the companies will hold a joint conference call to discuss the definitive share purchase agreement under which the stockholders of Daré Bioscience will become the majority owners of Cerulean.

Cerulean Pharma and Daré Bioscience Enter into Stock Purchase Agreement

3/20/2017 12:00 pm

[Business Wire] - Cerulean Pharma Inc. and Daré Bioscience, Inc., a privately-held, clinical-stage pharmaceutical company advancing products for women’s reproductive health, today announced that the two companies, together with the equityholders of Daré Bioscience, have entered into a definitive stock purchase agreement under which the equityholders of Daré Bioscience will become the majority owners of Cerulean.

Cerulean Pharma Attracts Investors and Possible Suitor, Protalix Returns to the Spotlight

3/14/2017 01:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 14, 2017 / The Biotech Sector is seeing the arrival of some new competitors, with one company continuing to overperform and another set to have its business absorbed or ...

Cerulean Announces Review of Strategic Alternatives

2/1/2017 01:00 pm

[Business Wire] - Cerulean Pharma Inc. , a clinical-stage company developing nanoparticle-drug conjugates , today announced that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value.

5 Stocks Poised for Major Breakouts--Gold, Pharma and Tech

12/4/2016 09:04 pm

[at TheStreet] - These stocks are within range of triggering breakout trades. Here's how to trade them from here.

Cerulean reports 3Q loss

11/4/2016 09:00 am

Cerulean reports 3Q loss

11/4/2016 09:00 am

Cerulean Reports Third Quarter 2016 Financial Results and Provides Corporate Update

11/3/2016 08:03 pm

[at noodls] - Conference Call Today at 4:30 p.m. ET WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update ...

Cerulean Reports Third Quarter 2016 Financial Results and Provides Corporate Update

11/3/2016 08:01 pm

[Business Wire] - Cerulean Pharma Inc. , a clinical-stage company developing nanoparticle-drug conjugates , today provided an update on corporate activities for the quarter ended September 30, 2016.

Cerulean to Host Third Quarter 2016 Conference Call on November 3

10/27/2016 11:02 am

[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities ...